Update on the Medical Treatment of Metastatic Renal Cell Carcinoma

European Urology

Volumn 54, Issue 2, 2008, Pages 315-325

  Ravaud, Alain ^a,b   Wallerand, Hervé ^c   Culine, Stéphane ^d,e   Bernhard, Jean Christophe ^c   Fergelot, Patricia ^f   Bensalah, Karim ^g,h   Patard, Jean Jacques ^g,h  

^a HÔPITAL SAINT ANDRÉ   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c HÔPITAL PELLEGRIN   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^f INSERM   (France)

^g PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^h UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Advanced renal cell carcinoma; Bevacizumab; Everolimus; Lapatinib; Renal cell carcinoma; Review; Sorafenib; Sunitinib; Targeted therapy; Temsirolimus

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN;

AREA UNDER THE CURVE; BLEEDING; BONE MARROW SUPPRESSION; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG MECHANISM; DRUG TARGETING; FATIGUE; HAND FOOT SYNDROME; HEART INFARCTION; HORMONAL THERAPY; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; KIDNEY CARCINOMA; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 45849094041     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.04.056     Document Type: Review

References (50)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Levi F., Lucchini F., Negri E., and La Vecchia C. Declining mortality from kidney cancer in Europe. Ann Oncol 15 (2004) 1130-1135
3. Godley P.A., and Taylor M. Renal cell carcinoma. Curr Opin Oncol 13 (2001) 199-203
4. Ravaud A., and Debled M. Present achievements in the medical treatment of metastatic renal cell carcinoma. Crit Rev Oncol Hematol 31 (1999) 77-87
5. US National Institutes of Health. Surveillance, Epidemiology and End Results (SEER) cancer statistics review: kidney and renal pelvis cancer; 5-yr relative survival rates, 1996-2002. Available at http://seer.cancer.gov/cgi-bin/csr/1975_2003/search.pl#results. Accessed March 24, 2008.
6. Patard J.-J., Rioux-Leclercq N., and Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 49 (2006) 633-643
7. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., et al. HIF1a targeted for VHL-mediated destruction by proline hydroxylation: implications for oxygen sensing. Science 292 (2001) 464-468
8. Kibel A., Illiopoulos O., Decaprio J.D., et al. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 269 (1995) 1444-1446
9. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2 (2002) 38-47
10. Gnarra J.R., Troy K., Weng Y., et al. Mutations of the VHL tumour suppressor gene in renal cell carcinoma. Nat Genet 7 (1994) 85-90
11. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumour suppressor protein VHL targets hypoxia inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
12. Illiopoulos O., Kibel A., Gray S., et al. Tumor suppression by the human von Hippel-Lindau gene product. Nat Med 1 (1995) 822-826
13. Kondo K., Kico J., Nakamura E., et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1 (2002) 237-246
14. Lidgren A., Hedberg Y., Grankvist K., Rasmuson T., Vasko J., and Ljungberg B. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 11 (2005) 1129-1135
15. Yao M., Yoshida M., Kishida T., Nakaigawa N., Baba M., Kobayashi K., et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 94 (2002) 1569-1575
16. Fergelot P., Rioux-Leclercq N., Zerrouki S., Bensalah K., and Patard J. Relationship between VHL mutation status, tumor VEGF expression and plasma VEGF measurement in sporadic renal cell carcinoma. Proc Am Soc Clin Oncol. J Clin Oncol 24 (2006) 4602
17. Rioux-Leclercq N., Fergelot P., Zerrouki S., et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol 38 (2007) 1498-1595
18. Hudson C.C., Liu M., Chiang G.G., et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22 (2002) 7004-7014
19. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev 18 (2004) 1926-1945
20. Pantuck A.J., Seligson D.B., Klatte T., et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109 (2007) 2257-2267
21. Ljungberg B., Hanbury D.C., Kuczyk M.A., et al. Renal cell carcinoma guideline. Eur Urol 51 (2007) 1502-1510
22. Motzer R.J., Michaelson M.D., and Redman B.G. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
23. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. Jama 295 (2006) 2516-2524
24. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
25. Ravaud A. Current options for the treatment of locally advanced and metastatic renal cell carcinoma: focus on sunitinib. Eur J Cancer 5 (2007) 4-11
26. Motzer R.J., Figlin R.A., Hutson T.E., et al. Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. Proc Am Soc Clin Oncol. J Clin Oncol 25 (2007) 5024
27. Houk B.E., Bello C.L., Michaelson M.D., et al. Exposure response of sunitinib in metastatic renal cell carcinoma (mRCC): a population pharmacokinetic/pharmacodynamic (PKPD) approach. Proc Am Soc Clin Oncol J Clin Oncol 25 (2007) 5027
28. Srinivas S., Roigas J., Gillessen S., et al. Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): updated results. Proc Am Soc Clin Oncol J Clin Oncol 25 (2007) 5040
29. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
30. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
31. Bukowski R.M., Kabbinavar F.F., Figlin R.A., et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 25 (2007) 4536-4541
32. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 356 (2007) 125-134
33. Bukowski R.M., Eisen T., Szczylik C., et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. Proc Am Soc Clin Oncol J Clin Oncol 25 (2007) 5023
34. Szczylik C., Demkow T., Staehler M., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. Proc Am Soc Clin Oncol J Clin Oncol 25 (2007) 5025
35. Amato R.J., Harris P., Dalton M., et al. A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). Proc Am Soc Clin Oncol J Clin Oncol 25 (2007) 5026
36. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
37. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
38. Dutcher J.P., Szczylik C., Tannir N., et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). Proc Am Soc Clin Oncol J Clin Oncol 25 (2007) 5033
39. Jac J., Giessinger S., Khan M., Willis J., Chiang S., and Amato R. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). Proc Am Soc Clin Oncol J Clin Oncol 25 (2007) 5107
40. Ravaud A, Hawkins R, Gardner J, et al. Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma (RCC). J Clin Oncol 2008:26 (in press).
41. Bhojani N., Jeldres C., Patard J.J., et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53 (2008) 917-930
42. Ravaud A. Key considerations in patient selection for the use of targeted therapy in metastatic renal cell carcinoma. Eur J Cancer 5 (2007) 20-27
43. Sablin M.P., Bouaita L., Balleyguier C., et al. Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients. Proc Am Soc Clin Oncol J Clin Oncol 25 (2007) 5038
44. George D.G., Michaelson M.D., Rosenberg J.E., et al. Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers. Proc Am Soc Clin Oncol J Clin Oncol 25 (2007) 5035
45. Feldman D.R., Kondagunta G.V., Ronnen E.A., et al. Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol J Clin Oncol 25 (2007) 5099
46. Azad N.S., Annunziata C., Barrett T., et al. Dual targeting of vascular endothelial growth factor (VEGF) with sorafenib and bevacizumab: clinical and translational results. Proc Am Soc Clin Oncol J Clin Oncol 25 (2007) 3542
47. Merchan J.R., Liu G., Fitch T., et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. Proc Am Soc Clin Oncol J Clin Oncol 25 (2007) 5034
48. Patnaik A., Ricart A., Cooper J., et al. A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 25 (2007) 3512
49. Choueiri T.K., Plantade A., Elson P., Negrier S., et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26 (2008) 127-131
50. Negrier S., Perol D., Ravaud A., et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110 (2007) 2468-2477